SER
Income statement / Annual
Last year (2024), Serina Therapeutics, Inc.'s total revenue was $56.00 K,
a decrease of 98.22% from the previous year.
In 2024, Serina Therapeutics, Inc.'s net income was -$11.14 M.
See Serina Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$56.00 K |
$3.15 M |
$500.00 K |
$3.04 M |
$54.00 K |
$1.73 M |
$1.40 M |
$1.40 M |
$1.67 M |
| Cost of Revenue |
$194.00 K
|
$90.00 K
|
$0.00
|
$0.00
|
$1.28 M
|
$998.50 K
|
$841.00 K
|
$685.00 K
|
$911.00 K
|
| Gross Profit |
-$138.00 K
|
$3.06 M
|
$500.00 K
|
$3.04 M
|
-$1.23 M
|
$729.50 K
|
$555.00 K
|
$719.00 K
|
$755.00 K
|
| Gross Profit Ratio |
-2.46
|
0.97
|
1
|
1
|
-22.72
|
0.42
|
0.4
|
0.51
|
0.45
|
| Research and Development Expenses |
$7.48 M
|
$2.39 M
|
$1.57 M
|
$3.80 M
|
$3.58 M
|
$5.35 M
|
$5.35 M
|
$5.27 M
|
$7.87 M
|
| General & Administrative Expenses |
$0.00
|
$3.89 M
|
$1.29 M
|
$1.30 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$9.43 M
|
$3.89 M
|
$1.29 M
|
$1.30 M
|
$5.60 M
|
$7.94 M
|
$5.65 M
|
$3.87 M
|
$5.62 M
|
| Other Expenses |
$0.00
|
-$90.00 K
|
-$91.50 K
|
-$425.57 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$16.91 M
|
$6.19 M
|
$2.77 M
|
$4.67 M
|
$9.18 M
|
$13.29 M
|
$11.00 M
|
$9.14 M
|
$13.49 M
|
| Cost And Expenses |
$17.10 M
|
$6.28 M
|
$2.77 M
|
$4.67 M
|
$10.46 M
|
$14.29 M
|
$11.84 M
|
$9.82 M
|
$14.41 M
|
| Interest Income |
$0.00
|
$0.00
|
$1.76 K
|
$10.86 K
|
$0.00
|
$29.00 K
|
$116.00 K
|
$0.00
|
$0.00
|
| Interest Expense |
$526.00 K
|
$558.00 K
|
$15.88 K
|
$3.09 K
|
$404.00 K
|
$0.00
|
$0.00
|
$12.00 K
|
$25.00 K
|
| Depreciation & Amortization |
$194.00 K
|
$90.00 K
|
$61.27 K
|
$33.37 K
|
$1.26 M
|
$951.00 K
|
$535.00 K
|
$682.00 K
|
$845.00 K
|
| EBITDA |
-$10.49 M |
$5.92 M |
-$2.60 M |
-$1.23 M |
-$8.74 M |
-$11.29 M |
-$7.20 M |
-$7.74 M |
-$11.89 M |
| EBITDA Ratio |
-187.27
|
1.88
|
-5.21
|
-0.4
|
-161.85
|
-6.53
|
-5.15
|
-5.51
|
-7.14
|
| Operating Income Ratio |
-304.43
|
-0.99
|
-4.54
|
-0.54
|
-192.72
|
-7.27
|
-7.48
|
-6
|
-7.65
|
| Total Other Income/Expenses Net |
$5.84 M
|
$8.40 M
|
-$411.74 K
|
$366.81 K
|
$8.00 K
|
$323.00 K
|
$2.71 M
|
$1.78 M
|
-$4.62 M
|
| Income Before Tax |
-$11.21 M
|
$5.27 M
|
-$2.68 M
|
-$1.26 M
|
-$10.40 M
|
-$12.24 M
|
-$7.73 M
|
-$6.64 M
|
-$17.36 M
|
| Income Before Tax Ratio |
-200.13
|
1.67
|
-5.36
|
-0.42
|
-192.57
|
-7.08
|
-5.54
|
-4.73
|
-10.42
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$148.00 K
|
$0.00
|
-$57.00 K
|
$0.00
|
| Net Income |
-$11.14 M
|
$5.27 M
|
-$2.68 M
|
-$1.26 M
|
-$10.87 M
|
-$12.15 M
|
-$7.50 M
|
-$6.58 M
|
-$15.49 M
|
| Net Income Ratio |
-198.95
|
1.67
|
-5.36
|
-0.42
|
-201.2
|
-7.03
|
-5.37
|
-4.69
|
-9.3
|
| EPS |
-1.51 |
0.63 |
-2.49 |
-8.05 |
-10.14 |
-11.47 |
-7.56 |
-6.46 |
-15.21 |
| EPS Diluted |
-1.51 |
0.63 |
-2.49 |
-8.05 |
-10.14 |
-11.47 |
-7.56 |
-6.46 |
-15.21 |
| Weighted Average Shares Out |
$7.36 M
|
$8.41 M
|
$1.08 M
|
$1.08 M
|
$1.07 M
|
$1.06 M
|
$992.72 K
|
$1.02 M
|
$1.02 M
|
| Weighted Average Shares Out Diluted |
$7.36 M
|
$8.41 M
|
$1.08 M
|
$1.08 M
|
$1.07 M
|
$1.06 M
|
$992.72 K
|
$1.02 M
|
$1.02 M
|
| Link |
|
|
|
|
|
|
|
|
|
